Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

Low-dose haloperidol is known to be effective for the treatment of postoperative nausea and vomiting (PONV). However, precise dose-response studies have not been completed, especially in patients at high risk for PONV who require combination therapy. This study sought to identify the optimal dose of haloperidol that could be combined with dexamethasone without adverse effects in high-risk PONV patients receiving intravenous patient-controlled anesthesia (IV PCA) after gynecological laparoscopic surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The Catholic University of Korea
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Haloperidol; Haloperidol decanoate

Criteria

Inclusion Criteria:

• ASA physical status I or II women

• Aged 20 65 years, and scheduled for gynecologic laparoscopic surgery and IV patient-controlled analgesia (PCA) for postoperative pain control.

Exclusion Criteria:

• Known allergy or intolerance to the study drug

• History of cardiac arrhythmia

• Psychiatric illness

• Chronic treatment with a dopamine antagonist

• Use of opioids or steroids within one week of surgery

• Use of antiemetic within 24 hours before the study

• No ability to use the PCA device

• Gastrointestinal, renal, or hepatic disease

• Insulin-dependent diabetes or obesity with a body mass index > 35 kg/m2.